CL2022001529A1 - Nuevos derivados de metilquinazolinona - Google Patents

Nuevos derivados de metilquinazolinona

Info

Publication number
CL2022001529A1
CL2022001529A1 CL2022001529A CL2022001529A CL2022001529A1 CL 2022001529 A1 CL2022001529 A1 CL 2022001529A1 CL 2022001529 A CL2022001529 A CL 2022001529A CL 2022001529 A CL2022001529 A CL 2022001529A CL 2022001529 A1 CL2022001529 A1 CL 2022001529A1
Authority
CL
Chile
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
CL2022001529A
Other languages
English (en)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Hunziker Daniel
Krummenacher Daniela
Francesco Tommaso Pettazzoni Piergiorgio
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022001529A1 publication Critical patent/CL2022001529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I), o una sal farmacéuticamente aceptable de este. El compuesto de Fórmula (I) se puede utilizar como medicamento.
CL2022001529A 2019-12-10 2022-06-09 Nuevos derivados de metilquinazolinona CL2022001529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10

Publications (1)

Publication Number Publication Date
CL2022001529A1 true CL2022001529A1 (es) 2023-02-10

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001529A CL2022001529A1 (es) 2019-12-10 2022-06-09 Nuevos derivados de metilquinazolinona

Country Status (18)

Country Link
US (2) US12116349B2 (es)
EP (1) EP4073065A1 (es)
JP (2) JP7108146B2 (es)
KR (1) KR20220110554A (es)
CN (2) CN114787156B (es)
AR (1) AR122351A1 (es)
AU (1) AU2020403443B2 (es)
CA (1) CA3162883A1 (es)
CL (1) CL2022001529A1 (es)
CO (1) CO2022008968A2 (es)
CR (1) CR20220251A (es)
IL (1) IL292161A (es)
MX (1) MX2022006783A (es)
PE (1) PE20221778A1 (es)
TW (1) TW202136245A (es)
UA (1) UA128299C2 (es)
WO (1) WO2021116055A1 (es)
ZA (1) ZA202204675B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006783A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona.
TW202313045A (zh) * 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
EP4352051A1 (en) * 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
KR20240008410A (ko) * 2021-06-09 2024-01-18 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
MX2024000965A (es) 2021-07-27 2024-02-09 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
CA3230652A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
TW202409040A (zh) * 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024105144A1 (en) 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024126634A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Process for the preparation of a quinazolinone derivative
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP6186440B2 (ja) 2012-09-19 2017-08-23 ノバルティス アーゲー キナーゼ阻害剤としてのジヒドロピロリジノピリミジン
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
CN107801378A (zh) * 2015-05-22 2018-03-13 普莱希科公司 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
US9890158B2 (en) 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
WO2021116050A1 (en) * 2019-12-10 2021-06-17 F. Hoffmann-La Roche Ag New braf inhibitors as paradox breakers
MX2022006783A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona.
CN116096710A (zh) 2020-06-09 2023-05-09 阿雷生物药品公司 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
CN116710451A (zh) 2020-12-18 2023-09-05 豪夫迈·罗氏有限公司 新的芳基-吡啶并-嘧啶-酮衍生物
CN116601147A (zh) 2020-12-18 2023-08-15 豪夫迈·罗氏有限公司 新喹唑啉酮衍生物
KR20240018446A (ko) 2021-06-08 2024-02-13 씨4 테라퓨틱스, 인코포레이티드 돌연변이 braf의 분해를 위한 요법
WO2023105371A1 (en) 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Also Published As

Publication number Publication date
CN114787156A (zh) 2022-07-22
CR20220251A (es) 2022-07-11
AR122351A1 (es) 2022-09-07
JP2022531609A (ja) 2022-07-07
US20220298119A1 (en) 2022-09-22
US12116349B2 (en) 2024-10-15
UA128299C2 (uk) 2024-05-29
WO2021116055A1 (en) 2021-06-17
EP4073065A1 (en) 2022-10-19
TW202136245A (zh) 2021-10-01
MX2022006783A (es) 2022-07-11
JP7108146B2 (ja) 2022-07-27
PE20221778A1 (es) 2022-11-16
ZA202204675B (en) 2022-12-21
BR112022011123A2 (pt) 2022-08-23
AU2020403443A1 (en) 2022-05-12
IL292161A (en) 2022-06-01
US20240174621A1 (en) 2024-05-30
CA3162883A1 (en) 2021-06-17
AU2020403443B2 (en) 2023-02-23
KR20220110554A (ko) 2022-08-08
JP2022124458A (ja) 2022-08-25
CN118791472A (zh) 2024-10-18
CO2022008968A2 (es) 2022-07-19
CN114787156B (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2020014586A2 (es) Compuestos
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CO2021016504A2 (es) Inhibidores de cdk
UY35362A (es) Compuestos terapéuticos
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR121226A1 (es) Compuestos y usos de estos
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2021008681A2 (es) Inhibidor de 15-pgdh
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
UY37941A (es) Derivados de bencimidazol y sus usos
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1